Christopher M. Carosino
Christopher M. Carosino has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Matthew R. Levengood
Pfizer, Inc., Bothell, Washington
84 shared publications - Melissa M.C. Dominguez
Cepheid, Bothell, Washington
74 shared publications - Shyra J. Gardai
EpiBiologics, San Mateo, California
74 shared publications - Weiping Zeng
Pfizer, Inc., Bothell, Washington
74 shared publications - Xinqun Zhang
Pfizer, Inc, Bothell, Washington
74 shared publications - David J. Ortiz
Pfizer, Inc., Bothell, Washington
62 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Supplementary Figure 1 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Supplementary Figure 1 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Data from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Non–muscle-invasive bladder cancer (NMIBC) accounts for 75% of all new bladder cancer diagnoses. Despite new therapeutic treatment options aiming to replace Bacillus Calmette–Guérin (BCG), the standard of care for 40+ years, high rates of failure and recurrence of disease remain in patients with NMIBC. Integrins are a large family of cell surface receptors involved in key biological processes such as cellular adhesion, motility, and cytokinesis, and integrin β-6 (IB6) has emerged as a clinically relevant target due to its restricted expression in normal adult epithelial tissues and elevated levels in solid tumors. IB6 is being actively tested in lung cancer with the antibody–drug conjugate (ADC) sigvotatug vedotin. In this study, we introduce PF-08052667, an IB6-directed ADC that has been optimized for local delivery via intravesical dosing in patients with NMIBC. PF-08052667 leverages the high and consistent expression of IB6 in NMIBC tumors for efficient ADC internalization. In PF-08052667, an average of 8 monomethyl auristatin E molecules are attached to an IB6-specific humanized IgG1 antibody via a glucuronide linker shown to increase potency in vitro. PF-08052667 efficacy was further optimized when administered after a bladder prewash, which improved ADC delivery to the bladder tissue. The combination of highly potent PF-08052667 with bladder prewash demonstrated enhanced in vivo efficacy while maintaining minimal systemic exposure and no systemic toxicity. Together, the results position PF-08052667 as a potential first-in-class ADC optimized for intravesical delivery and support further clinical examination in an ongoing phase I trial testing safety and efficacy in BCG-unresponsive and BCG-exposed NMIBC (NCT07206225).
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Non–muscle-invasive bladder cancer (NMIBC) accounts for 75% of all new bladder cancer diagnoses. Despite new therapeutic treatment options aiming to replace Bacillus Calmette–Guérin (BCG), the standard of care for 40+ years, high rates of failure and recurrence of disease remain in patients with NMIBC. Integrins are a large family of cell surface receptors involved in key biological processes such as cellular adhesion, motility, and cytokinesis, and integrin β-6 (IB6) has emerged as a clinically relevant target due to its restricted expression in normal adult epithelial tissues and elevated levels in solid tumors. IB6 is being actively tested in lung cancer with the antibody–drug conjugate (ADC) sigvotatug vedotin. In this study, we introduce PF-08052667, an IB6-directed ADC that has been optimized for local delivery via intravesical dosing in patients with NMIBC. PF-08052667 leverages the high and consistent expression of IB6 in NMIBC tumors for efficient ADC internalization. In PF-08052667, an average of 8 monomethyl auristatin E molecules are attached to an IB6-specific humanized IgG1 antibody via a glucuronide linker shown to increase potency in vitro. PF-08052667 efficacy was further optimized when administered after a bladder prewash, which improved ADC delivery to the bladder tissue. The combination of highly potent PF-08052667 with bladder prewash demonstrated enhanced in vivo efficacy while maintaining minimal systemic exposure and no systemic toxicity. Together, the results position PF-08052667 as a potential first-in-class ADC optimized for intravesical delivery and support further clinical examination in an ongoing phase I trial testing safety and efficacy in BCG-unresponsive and BCG-exposed NMIBC (NCT07206225).
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Representative analytical results for PF-0805266
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Representative analytical results for PF-0805266
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Intracellular trafficking and localization of PF-08052667
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Intracellular trafficking and localization of PF-08052667
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Saturation binding analysis of h2A2 antibody and PF-08052667 on UMUC3 parental and engineered cell lines
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Saturation binding analysis of h2A2 antibody and PF-08052667 on UMUC3 parental and engineered cell lines
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
1B6 expression and efficacy on patient-derived organoids (PDOs)
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
1B6 expression and efficacy on patient-derived organoids (PDOs)
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
SW780 mouse model plots of individual mice
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
SW780 mouse model plots of individual mice
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
UMUC3-1B6+RL+ mouse model plots of individual mice and CR rates
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
UMUC3-1B6+RL+ mouse model plots of individual mice and CR rates
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Table 3. MMP2 and MMP9 quantification from select tumor models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Table 3. MMP2 and MMP9 quantification from select tumor models.